Liver and biliary tract cancer trials in Spain
56 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 13 November 2026. Ask the study team whether a trial fits you.
- Phase 1Taking peopleStudy of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Where
- Badajoz, Barcelona, Madrid, Pamplona, Santander, Sevilla, Valencia
- Age
- 18 years and over
- People
- 1,394 worldwide
- Run by
- Exelixis
See details and how to joinNCT05176483 · EU 2023-510061-10-00 - Phase 2Taking peopleAZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
- Where
- Barcelona, Madrid
- Age
- 18 years and over
- People
- 226 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06219941 · EU 2023-508275-37-00 - Phase 3Taking peopleA Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
- Where
- Barcelona, L'Hospitalet de Llobregat, Madrid, Santander
- Age
- 18 years and over
- People
- 1,100 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07221253 · EU 2025-523085-24-00 - Phase 2Taking peopleStudy of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Where
- Barcelona, Córdoba, Madrid, Málaga, Sevilla
- Age
- 18 years to 130 years
- People
- 454 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05489211 · EU 2023-509436-26-00 - Phase 1Taking peopleA Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
- Where
- Madrid
- Age
- 18 years and over
- People
- 232 worldwide
- Run by
- AbbVie
See details and how to joinNCT06858813 · EU 2024-518012-39-00 - Phase 1/2Taking peopleSafety of HRX215 in Patients After Minor and Major Liver Resection
- Where
- Madrid, Valencia
- Age
- 18 years to 75 years
- People
- 80 worldwide
- Run by
- HepaRegeniX GmbH
See details and how to joinNCT06638502 - Phase 1/2Taking peopleSafety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
- Where
- Barcelona, Madrid, Málaga, Seville
- Age
- 18 years and over
- People
- 225 worldwide
- Run by
- Tango Therapeutics, Inc.
See details and how to joinNCT05732831 - Phase 2Taking peopleStudy of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
- Where
- Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona
- Age
- 18 years and over
- People
- 120 worldwide
- Run by
- Taiho Oncology, Inc.
See details and how to joinNCT05727176 · EU 2023-503665-39-00 - Phase 3Taking peopleA Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician’s Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR) altered, Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308)
- Where
- Barcelona, Córdoba, Madrid, Pamplona, Santiago de Compostela, Zaragoza
- Age
- 18 years and over
- People
- 126 worldwide
- Run by
- Transthera Sciences (Nanjing) Inc.
See details and how to join2023-505660-11-00 - Phase 2Taking peopleA Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Where
- Barcelona, Madrid, Santiago de Compostela, Sevilla, Valencia
- Age
- 8 years and over
- People
- 254 worldwide
- Run by
- Fore Biotherapeutics
See details and how to joinNCT05503797 · EU 2024-513578-23-00 - Phase 1Taking peopleA Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- Where
- Barcelona, L'Hospitalet de Llobregat, Madrid
- Age
- 18 years and over
- People
- 714 worldwide
- Run by
- Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT05208762 · EU 2023-506604-18-00 - Phase 2Taking peopleRandomized Study to Evaluate Melphalan/HDS Treatment Followed by Trifluridine–tipiracil plus Bevacizumab Versus Trifluridine–tipiracil plus Bevacizumab Alone in Metastatic Colorectal Cancer Patients
- Where
- Barcelona, L'Hospitalet de Llobregat, Madrid
- Age
- 18 years and over
- People
- 35 worldwide
- Run by
- Delcath Systems Inc.
See details and how to join2024-520356-24-00 - No phaseTaking peopleUnravelling the Impact of Radiofrecuency in Liver Surgery: the Key to Decrease Local Recurrence?
- Where
- Barcelona
- Age
- 18 years and over
- People
- 720
- Run by
- Hospital del Mar
See details and how to joinNCT05492136 - No phaseTaking peopleDRAGON Registry - International Multicenter Registry and Medical Image Bank for Patients With Primarily Unresectable Liver Cancer or Liver Metastases That Underwent Combined Portal and Hepatic Vein Embolization (PVE/HVE) to Increase Future Liver Remnant Before Resection.
- Where
- Badalona, Barcelona
- Age
- 18 years and over
- People
- 350 worldwide
- Run by
- Maastricht University Medical Center
See details and how to joinNCT07717437 - Phase 2Taking peopleStudy to Evaluate the Efficacy and Safety of Atezolizumab and Bevacizumab as Neoadjuvant Plus Adjuvant Treatment in HCC
- Where
- Badalona, Barakaldo, Barcelona, Córdoba, Girona, Madrid, Málaga, Santander, Valencia
- Age
- 18 years and over
- People
- 90
- Run by
- Fundacion Clinic per a la Recerca Biomédica
See details and how to joinNCT07018947 · EU 2025-521459-22-00 - Phase 1/2Taking peopleA Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
- Where
- Barcelona, Córdoba, El Palmar, Madrid, Seville, Tarragona, Valencia
- Age
- 18 years and over
- People
- 180 worldwide
- Run by
- Alentis Therapeutics AG
See details and how to joinNCT07169734 · EU 2025-521441-24-00 - Phase 1Taking peopleIs CT 01 safe to use alone or combined with Everolimus for inoperable advanced liver cancer?
- Where
- Barcelona, Madrid, Valencia
- Age
- 18 years and over
- People
- 154 worldwide
- Run by
- Captor Therapeutics S.A.
See details and how to join2024-511435-10-00 - No phaseTaking peopleLiver Transplant Combined With Neoadjuvant Chemo-radiotherapy in the Treatment of Unresectable Perihilar Cholangiocarcinoma. A Prospective Multicenter Study.
- Where
- Barcelona
- Age
- 18 years to 70 years
- People
- 34
- Run by
- Hospital Vall d'Hebron
See details and how to joinNCT04378023 - Phase 4Taking peopleA Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3
- Where
- Barcelona, Madrid, Valencia
- Age
- 18 years and over
- People
- 50 worldwide
- Run by
- Replimune, Inc.
See details and how to joinNCT06887348 · EU 2025-521621-33-00 - No phaseEnrolling by invitationAnalysis of the Incidence of Cholangiocarcinoma on Choledochal Cyst in a Western Center
- Where
- Huelva
- People
- 300
- Run by
- María Teresa Moreno Asencio
See details and how to joinNCT05404503 - Phase 4Taking peopleHOPE Against Cancer Recurrence in HCC
- Where
- Barcelona
- Age
- 18 years and over
- People
- 220 worldwide
- Run by
- Philipp Dutkowski
See details and how to joinNCT06717919 - No phaseEnrolling by invitationPrehabilitation and Posttransplant Training Program in Liver Transplantation
- Where
- Valencia
- Age
- 18 years and over
- People
- 60
- Run by
- Maria dels Angels Cebria i Iranzo, PT, PhD
See details and how to joinNCT04246970 - No phaseEnrolling by invitationInternational Registry of Congenital Portosystemic Shunt (IRCPSS)
- Where
- Barcelona
- Age
- 1 day and over
- People
- 500 worldwide
- Run by
- Prof. Valérie Mc Lin
See details and how to joinNCT06041906 - Phase 2Not yet taking people in SpainA Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC
- Where
- Barcelona, Madrid, Oviedo, Pamplona
- Age
- 18 years and over
- People
- 120 worldwide
- Run by
- Akeso
See details and how to joinNCT06984718 · EU 2025-524591-30-00 - Phase 3Taking peopleThe ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma
- Where
- Alcorcón, Alicante, Badajoz, Badalona, Barcelona, Cadiz, Jaén, Madrid, Majadahonda, Málaga, Santander, Sevilla
- Age
- 18 years and over
- People
- 434 worldwide
- Run by
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
See details and how to joinNCT04803994 · EU 2024-512953-26-00